Serum osteopontin levels in relation to bone mineral density and bone turnover markers in postmenopausal women

References

• Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013;24:23–57.
   PubMed Web of Science ®Google Scholar
• Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011;377:1276–87.
   PubMed Web of Science ®Google Scholar
• Walker CG, Dangaria S, Ito Y, Luan X, Diekwisch TG. Osteopontin is required for unloading-induced osteoclast recruitment and modulation of RANKL expression during tooth drift-associated bone remodeling, but not for super-eruption. Bone 2010;47:1020–9.
   PubMed Web of Science ®Google Scholar
• Huang W, Carlsen B, Rudkin G, Berry M, Ishida K, Yamaguchi DT, Miller TA. Osteopontin is a negative regulator of proliferation and differentiation in MC3T3-E1 pre-osteoblastic cells. Bone 2004;34:799–808.
   PubMed Web of Science ®Google Scholar
• Franzén A, Hultenby K, Reinholt FP, Onnerfjord P, Heinegård D. Altered osteoclast development and function in osteopontin deficient mice. J Orthop Res 2008;26:721–8.
   PubMed Web of Science ®Google Scholar
• Yoshitake H, Rittling SR, Denhardt DT, Noda M. Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci USA 1999;96:8156–60.
   PubMed Web of Science ®Google Scholar
• Ishijima M, Rittling SR, Yamashita T, Tsuji K, Kurosawa H, Nifuji A, Denhardt DT, Noda M. Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin. J Exp Med 2001;193:399–404.
   PubMed Web of Science ®Google Scholar
• Ishijima M, Ezura Y, Tsuji K, Rittling SR, Kurosawa H, Denhardt DT, Emi M, Nifuji A, Noda M. Osteopontin is associated with nuclear factor kappaB gene expression during tail-suspension-induced bone loss. Exp Cell Res 2006;312:3075–83.
   PubMed Web of Science ®Google Scholar
• Cho EH, Cho KH, Lee HA, Kim SW. High serum osteopontin levels are associated with low bone mineral density in postmenopausalwomen. J Korean Med Sci 2013;28:1496–9.
   PubMed Web of Science ®Google Scholar
• Fodor D, Bondor C, Albu A, Simon SP, Craciun A, Muntean L. The value of osteopontin in the assessment of bone mineral density status in postmenopausal women. J Investig Med 2013;61:15–21.
   PubMed Web of Science ®Google Scholar
• Chang IC, Chiang TI, Yeh KT, Lee H, Cheng YW. Increased serum osteopontin is a risk factor for osteoporosis in menopausal women. Osteoporos Int 2010;21:1401–9.
   PubMed Web of Science ®Google Scholar
• Méndez JP, Rojano-Mejía D, Pedraza J, Coral-Vázquez RM, Soriano R, García-García E, Aguirre-García Mdel C, Coronel A, Canto P. Bone mineral density in postmenopausal Mexican-Mestizo women with normal body mass index, overweight, or obesity. Menopause 2013;20:568–72.
   PubMed Web of Science ®Google Scholar
• Gómez-Ambrosi J, Catalán V, Ramírez B, Rodríguez A, Colina I, Silva C, Rotellar F, Mugueta C, Gil MJ, Cienfuegos JA, Salvador J, Frühbeck G. Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab 2007;92:3719–27.
   PubMed Web of Science ®Google Scholar
• Lu HK, Zhang Z, Ke YH, He JW, Fu WZ, Zhang CQ, Zhang ZL. High prevalence of vitamin D insufficiency in China: relationship with the levels of parathyroid hormone and markers of bone turnover. PLoS One 2012;7:e47264.
   PubMed Web of Science ®Google Scholar
• Garnero P, Munoz F, Sornay-Rendu E. Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study. Bone 2007;40:716–22.
   PubMed Web of Science ®Google Scholar
• El Maghraoui A, Ouzzif Z, Mounach A, Rezqi A, Achemlal L, Bezza A, Tellal S, Dehhaoui M, Ghozlani I. Hypovitaminosis D and prevalent asymptomatic vertebral fractures in Moroccan postmenopausal women. BMC Womens Health 2012;12:11.
   PubMed Web of Science ®Google Scholar
• Mehrotra RN, Ranjan A, Lath R. Postmenopausal osteoporosis: our experience. Indian J Endocrinol Metab 2012;16:S421–2.
   PubMedGoogle Scholar
• von Mühlen DG, Greendale GA, Garland CF, Wan L, Barrett-Connor E. Vitamin D, parathyroid hormone levels and bone mineral density in community-dwelling older women: the Rancho Bernardo Study. Osteoporos Int 2005;16:1721–6.
   PubMed Web of Science ®Google Scholar
• van der Meijden K, Lips P, van Driel M, Heijboer AC, Schulten EA, den Heijer M, Bravenboer N. Primary human osteoblasts in response to 25-hydroxyvitamin D3, 1,25-dihydroxyvitamin D3 and 24R,25-dihydroxyvitamin D3. PLoS One 2014;9:e110283.
   PubMed Web of Science ®Google Scholar
• Suda T, Masuyama R, Bouillon R, Carmeliet G. Physiological functions of vitamin D: what we have learned from global and conditional VDR knockout mouse studies. Curr Opin Pharmacol 2015;22:87–99.
   PubMed Web of Science ®Google Scholar
• Chiang TI, Chang IC, Lee HS, Lee H, Huang CH, Cheng YW. Osteopontin regulates anabolic effect in human menopausal osteoporosis with intermittent parathyroid hormonetreatment. Osteoporos Int 2011;22:577–85.
   PubMed Web of Science ®Google Scholar
• Albadah MS, Dekhil H, Shaik SA, Alsaif MA, Shogair M, Nawaz S, Alfadda AA. Effect of weight loss on serum osteocalcin and its association with serum adipokines. Int J Endocrinol 2015;2015:508532.
   PubMed Web of Science ®Google Scholar
• Garnero P, Grimaux M, Seguin P, Delmas PD. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res 1994;9:255–64.
   PubMed Web of Science ®Google Scholar
• Nagasue K, Inaba M, Okuno S, Kitatani K, Imanishi Y, Ishimura E, Miki T, Kim M, Nishizawa Y. Serum N-terminal midfragment vs. intact osteocalcin immunoradiometric assay as markers for bone turnover and bone loss in hemodialysis patients. Biomed Pharmacother 2003;57: 98–104.
   PubMed Web of Science ®Google Scholar
• Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways. J Bone Miner Res 2011;26:644–56.
   PubMed Web of Science ®Google Scholar
• Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003;111:1221–30.
   PubMed Web of Science ®Google Scholar